论文部分内容阅读
自高密度脂蛋白胆固醉(HDL—C)的水平与冠心病的发病率呈负相关被确认以来,它的测定便引起了人们的广泛关注。由于高密度脂蛋白在肝脏合成与代谢,肾脏疾病又有动脉粥硬化的危险因子存在,故当肝脏与肾脏发病时其血清中 HDL—C 亦会变化,本文对常见肝病和肾病患者的 HDL—C 进行了测定,介绍如下。1 对象和方法肾病综合征16例,慢性肾炎28例,急性肝炎34例,慢性肝炎31例(其中男18例,女13例),肝硬化19例,健康人对照组57例。受调查者均空腹采血,1h后分离血清,当日检测完毕,测定使用北京中生生物工程高技术公司的试剂盒。
Since the level of HDL-C was negatively correlated with the incidence of coronary heart disease, its determination has attracted much attention. Because HDL synthesis and metabolism in the liver, kidney disease and atherosclerosis risk factors exist, so when the liver and kidney disease serum HDL-C will change, this article on common liver disease and kidney disease in patients with HDL- C were measured, described below. 1 Subjects and Methods Nephrotic syndrome in 16 cases, 28 cases of chronic nephritis, acute hepatitis in 34 cases, 31 cases of chronic hepatitis (including 18 males and 13 females), liver cirrhosis in 19 cases, 57 healthy controls. The respondents were fasting blood, serum was separated after 1h, the day the test is completed, the determination of using Beijing Bio-engineering high-tech companies kit.